Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
Julie E. Bauman(George Washington University), Roger B. Cohen(University of Pennsylvania), Diego Alvarado(Unknown), Nabil F. Saba(Emory University), Mary J. Fidler, Umamaheswar Duvvuri(City University of New York), Trisha M. Wise‐Draper(University of Cincinnati), Douglas R. Adkins(Washington University in St. Louis), Ricklie Julian(University of Arizona), Paul E. O’Brien(Medical University of South Carolina), Margo Heath‐Chiozzi(Celldex Therapeutics (United States)), Michael K. Gibson(Vanderbilt University), Philip Golden(Celldex Therapeutics (United States)), Richard Gedrich(Arvinas (United States))
Cited by 11
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Head and neck cancer
|The Lancet|2021|829